Source: Eur Respir J 2016; 48: 1268-1270



Rating:

Share or cite this content

Citations should be made in the following way:
Pierre-Marie Roy. Prolonged anticoagulation in VTE with direct oral anticoagulants: towards an individual analysis of net clinical benefit?. Eur Respir J 2016; 48: 1268-1270

Member's Comments

No comment yet.

Related content which might interest you: Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020 Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials Source: Eur Respir J, 50 (3) 1701097; 10.1183/13993003.01097-2017 Year: 2017 Anticoagulant treatment of venous thromboembolism: established and new oral agents, remaining questions Source: International Congress 2014 – Current controversies in the management of acute pulmonary embolism Year: 2014 A single centre experience of low dose direct oral anticoagulants (DOAC) after unprovoked venous thromboembolism (VTE) Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019 Initial anticoagulant treatment and home treatment of PE Source: ERS Course 2019 - Masterclass in pulmonary embolism Year: 2019 Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Update on novel anticoagulants: indications, dosing alternatives and outcomes Source: International Congress 2018 – Pulmonary embolism: what we need to know Year: 2018 Direct - acting oral anticoagulants: which agent for which patient? Source: International Congress 2019 – Update on anticoagulant therapy: controversy and progress Year: 2019 Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019 Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? Source: Eur Respir J, 55 (1) 1902028; 10.1183/13993003.02028-2019 Year: 2020 Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? Source: Eur Respir J, 55 (1) 1902323; 10.1183/13993003.02323-2019 Year: 2020 Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment Source: Eur Respir J 2016; 48: 1369-1376 Year: 2016 Should thrombolysis and sildenafil be given in the acute management of patients with large pulmonary embolism? An assessment of the short and long-term outcomes. Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019 Oral anticoagulation therapy in pediatric pulmonary hypertension: A 10-year registry survival analysis Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010 Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Efficacy and safety of treatment with anticoagulants in patients with unprovoked venous thromboembolism in Korea Source: International Congress 2016 – Acute pulmonary embolism Year: 2016 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 Efficacy and safety of systemic and prolonged low-dose thrombolysis in thromboembolic disease Source: Eur Respir J 2002; 20: Suppl. 38, 478s Year: 2002 How can we minimise the use of regular oral corticosteroids in asthma? Source: Eur Respir Rev, 29 (155) 190085; 10.1183/16000617.0085-2019 Year: 2020 Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021